Logo
x

Search

Subscribe Now

UC

Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis

Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis

  • July 12, 2021
AbbVie Report Results of Rinvoq (upadacitinib) in P-III Maintenance Study for the Treatment of Ulcerative Colitis

AbbVie Report Results of Rinvoq (upadacitinib) in P-III Maintenance Study for the Treatment of Ulcerative Colitis

  • June 30, 2021
Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligi...

  • May 21, 2021
Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Cancer (UC)

Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Ca...

  • January 25, 2019
Janssen (J&J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severely Active Ulcerative Colitis (UC)

Janssen (J&J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severe...

  • January 9, 2019
Sandoz's Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

Sandoz's Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

  • October 31, 2018
Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US

    Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US

    • March 7, 2025
    Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patients

      Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study Evaluating Enhertu in HER2+ Metastatic Gastric Cancer Patie...

      • March 4, 2025
      Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for ~$4.1B

        Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for ~$4.1B

        • February 26, 2025
        GSK Reports the China’s NMPA Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD

          GSK Reports the China’s NMPA Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD

          • February 20, 2025
          Cumberland Pharmaceuticals Reveals Topline Data from P-II (FIGHT DMD) Trial of Ifetroban for Duchenne Muscular Dystrophy Heart Disease

            Cumberland Pharmaceuticals Reveals Topline Data from P-II (FIGHT DMD) Trial of Ifetroban for Duchenne Muscular Dystrophy Heart Dis...

            • February 5, 2025
            Roche Reveals Data from P-III (EMBARK) Study of Elevidys in Ambulatory Boys with Duchenne Muscular Dystrophy

              Roche Reveals Data from P-III (EMBARK) Study of Elevidys in Ambulatory Boys with Duchenne Muscular Dystrophy

              • January 28, 2025
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.